{"result": "(\"entity\"<|>IPILIMUMAB<|>ORGANIZATION<|>Ipilimumab is a drug used in immunotherapy for various tumors, including melanoma, and is not associated with causing hyperprolactinemia but rather hormone deficiencies.)\n##\n(\"entity\"<|>CABERGOLINA<|>ORGANIZATION<|>Cabergoline is a medication used to treat conditions associated with high levels of prolactin, such as prolactinomas.)\n##\n(\"entity\"<|>BROMOCRIPTINA<|>ORGANIZATION<|>Bromocriptine is a medication that can be used to manage hyperprolactinemia and is an agonist of dopamine receptors.)\n##\n(\"entity\"<|>MICROPROLACTINOMA<|>EVENT<|>Microprolactinoma is a small tumor of the pituitary gland that produces excess prolactin, affecting hormonal balance and potentially fertility.)\n##\n(\"entity\"<|>MADRID<|>GEO<|>Madrid is the capital of Spain and the location of the Sociedad Española de Endocrinología y Nutrición, which published the referenced manual.)\n##\n(\"entity\"<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Spanish Society of Endocrinology and Nutrition is a professional organization that provides guidelines and resources related to endocrinology and nutrition.)\n##\n(\"entity\"<|>PACIENTE<|>PERSON<|>The patient is a 20-week pregnant woman diagnosed with a microprolactinoma who has suspended treatment with cabergoline.)\n##\n(\"relationship\"<|>PACIENTE<|>MICROPROLACTINOMA<|>The patient has been diagnosed with a microprolactinoma, which is affecting her treatment options during pregnancy.<|>8)\n##\n(\"relationship\"<|>CABERGOLINA<|>PACIENTE<|>The patient suspended treatment with cabergoline one month before her pregnancy due to her microprolactinoma.<|>7)\n##\n(\"relationship\"<|>BROMOCRIPTINA<|>PACIENTE<|>The patient is considering bromocriptine as a treatment option for managing her microprolactinoma during lactation.<|>6)\n##\n(\"relationship\"<|>IPILIMUMAB<|>MICROPROLACTINOMA<|>Ipilimumab is mentioned in the context of its effects on hormone levels, which can be relevant for patients with microprolactinomas.<|>4)\n##\n(\"relationship\"<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>MADRID<|>The Spanish Society of Endocrinology and Nutrition is based in Madrid and provides resources for endocrinology practices.<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: icas de hiperprolactinemia, señale\n          años de tratamiento, el paciente mantiene normoprolactinemia y el tumor ha desaparecido.                                                    la afirmación incorrecta:\n        En caso de persistir restos tumorales no es aconsejable suspender el tratamiento por el                                                       A. El ipilimumab provoca hiperprolactinemia porque antagoniza el receptor D2 de la\n        elevado riesgo de recurrencia, salvo que se trate de un microprolactinoma (respuestas A                                                           dopamina.\n        y B falsas). En este caso se podría plantear la suspensión del tratamiento, aunque queden\n        restos tumorales, pero estos pacientes precisarían un seguimiento estrecho para detectar                                                      B. Los inhibidores de la recaptación de serotonina (como la fluoxetina y la paroxetina) no\n        recurrencias y reinstaurar el tratamiento si se requiere.                                                                                         producen hiperprolactinemia significativa.\n        En caso de decidir suspender el tratamiento, se debe programar vigilancia estricta en el                                                      C. La hiperprolactinemia provocada por antipsicóticos se resuelve con rapidez (2-4 días)\n        primer año tras la retirada, ya que este es el período más probable para la recurrencia. Si la                                                    tras la suspensión de los mismos.\n        situación del paciente dificultase realizar el seguimiento como se requiere, es preferible no                                                 D.  El verapamilo puede provocar hiperprolactinemia.\n        suspender completamente los agonistas dopaminérgicos.\n        Referencias:                                                                                                                                  COMENTARIO\n        • Torres Vela E, López Mezquita Torres E. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de Endocrinolo-\n          gía y Nutrición; 2015. Capítulo 12. Hiperprolactinemias [citado 29 de abril de 2019]. Disponible en: https://manual.seen.es/article?i-      Fármacos e hiperprolactinemia\n          d=55114b5e-a308-47b0-89af-2bcdac18103c\n                                                                                                                                                      Tal como se comentó en la pregunta 27, son múltiples fármacos los que se relacionan con la\n                                                                                                                                                      aparición de hiperprolactinemia. Por tanto, ante una elevación de prolactina no fisiológica,\n    31  Acude a nuestra consulta una paciente gestante de 20 semanas, diagnosticada                                                                   el origen farmacológico debe descartarse, antes de investigar otras opciones patológicas.\n        de un microprolactinoma de 9 mm, que suspendió el tratamiento con cabergolina 1 mes                                                           Los antidepresivos son causa común de hiperprolactinemia, aunque esta es más eviden-\n        antes de la gestación. Nos plantea que desea amamantar a su bebé cuando nazca.                                                                te con los tricíclicos, mientras que con los inhibidores de la recaptación de serotonina la\n        ¿Qué respuesta considera más adecuada?                                                                                                        elevación de prolactina es menor y suele ser poco significativa (respuesta B). Algunos anti-\n        A. No es recomendable por el riesgo de aumento del adenoma.                                                                                   hipertensivos, entre los que se encuentra el verapamilo, también se asocian a hiperprolac-\n        B. No hay contraindicación para la lactancia.                                                                                                 tinemia (respuesta D). Sin embargo, los antipsicóticos son los responsables de la mayoría\n                                                                                                                                                      de hiperprolactinemias farmacológicas en la clínica. Algunos de ellos son antagonistas\n        C. Es recomendable solo si realiza tratamiento con cabergolina.                                                                               del receptor D2 de la dopamina, y es el mecanismo que justifica la elevación de la PRL. El\n        D.  Es recomendable solo si realiza tratamiento con bromocriptina.                                                                            aumento de PRL se inicia en las primeras horas tras la administración del fármaco y vuelve\n                                                                                                                                                      a la normalidad entre 2 y 4 días tras la interrupción de la terapia (respuesta C).\n\n\n\n42                                                                                                                                                                                                                                                                              43\n---\n                                                                                                                                                                                                                                                                                        HIPÓFISIS                               1\n\n\n\n        Hipofisitis por ipilimumab                                                                                                                                    Correlación entre etiología y niveles de PRL. El grado de elevación de los niveles de PRL\n        El ipilimumab es un fármaco que no causa hiperprolactinemia, sino déficit de hormonas hi-                                                                     se    puede       correlacionar con la etiología (fig. 2). Cuando la hiperprolactinemia                                                   es de    causa\n        pofisarias (incluida la PRL), por hipofisitis (opción A falsa: respuesta correcta). Este fármaco                                                              farmacológica, en la mayoría de los casos no va a superar los 100 ng/ml, salvo la risperidona,\n        forma parte de la inmunoterapia empleada en diferentes tumores, como el melanoma, y la                                                                        que puede producir aumentos de hasta 300-400\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}